Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

An update from Fennec Pharmaceuticals ( ($TSE:FRX) ) is now available. Fennec Pharmaceuticals has announced that the University of Arizona Cancer C...

Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers

The latest announcement is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals reported record 2025 net PEDMARK sales of $44.6 m...

Fennec Posts Record PEDMARK Sales in 2025 as Clinical and Commercial Momentum Builds

Piper Sandler analyst David Amsellem reiterated a Buy rating on Fennec Pharmaceuticals today and set a price target of $18.00. According to TipRank...

Piper Sandler Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an announcement. Fennec Pharmaceuticals reported record 2025 results, with PEDMARK net product sal...

Fennec Pharmaceuticals Posts Record PEDMARK Sales and Broadens Clinical Footprint in 2025

The latest announcement is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals will release its full-year and fourth-quarter 202...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FENC	$6.49	+2.61%	125.73K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FENC	$6.49	+2.6%	125.73K
3
4
5
6

FENC

FENC

No Data Available

Get Fennec Pharmaceuticals Inc. Data in Excel

Get Fennec Pharmaceuticals Inc. Data in Excel